- Sections
- C - Chimie; métallurgie
- C07D - Composés hétérocycliques
- C07D 281/18 - Cycles à huit chaînons
Détention brevets de la classe C07D 281/18
Brevets de cette classe: 19
Historique des publications depuis 10 ans
2
|
1
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Propriétaires principaux
Proprétaire |
Total
|
Cette classe
|
---|---|---|
Neurovive Pharmaceutical AB | 15 |
2 |
Merck Sharp & Dohme LLC | 3689 |
2 |
Bristol-myers Squibb Company | 5080 |
1 |
AstraZeneca UK Limited | 768 |
1 |
FUJIFILM Corporation | 27102 |
1 |
Alfa Wassermann S.p.A. | 22 |
1 |
Kosan Biosciences, Inc. | 55 |
1 |
Phenex Pharmaceuticals AG | 22 |
1 |
Rutgers, The State University of New Jersey | 1776 |
1 |
Salix Pharmaceuticals, Ltd. | 48 |
1 |
Santen Pharmaceutical Co., Ltd. | 649 |
1 |
Stanford University | 62 |
1 |
State of Oregon acting by and through the State Board of Higher Education on behalf of Portland State University | 11 |
1 |
Tomoegawa Co., Ltd. | 252 |
1 |
Ube Industries, Ltd. | 921 |
1 |
The United States of America, as represented by the Secretary, Department of Health and Human Services | 2737 |
1 |
Cothera BioScience, Inc. | 16 |
1 |
Autres propriétaires | 0 |